Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04787042 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | recruiting | Phase 1 / Phase 2 | 316 | Simcha IL-18, Inc.INDUSTRY | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06240143 | Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma(MARIANE) | recruiting | Phase 1 / Phase 2 | 96 | The Netherlands Cancer InstituteOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT03341143 | Fecal Microbiota Transplant (FMT) in Melanoma Patients | completed | Phase 2 | 20 | Zarour, Hassane, MDOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT06651151 | NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma(NeoLIPA) | recruiting | Phase 2 | 27 | Oslo University HospitalOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT04091217 | Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma | completed | Phase 2 | 43 | Hoffmann-La RocheINDUSTRY | 1 | Oct 24, 2024 | clinicaltrials |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | terminated | Phase 2 | 40 | Rain Oncology IncINDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT03207867 | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma | terminated | Phase 2 | 315 | Novartis PharmaceuticalsINDUSTRY | 15 | Oct 9, 2024 | clinicaltrials |
| NCT03776136 | Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004) | completed | Phase 2 | 103 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Oct 9, 2024 | clinicaltrials |
| NCT01740557 | Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma | completed | Phase 1 / Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT02027935 | CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT00863330 | Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma | terminated | Phase 2 | 14 | Wake Forest University Health SciencesOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT03476174 | Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma | terminated | Phase 2 | 1 | Ralph HaukeOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT03200847 | Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma | completed | Phase 1 / Phase 2 | 26 | University of Colorado, DenverOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT03448666 | ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases | withdrawn | Phase 2 | 0 | European Institute of OncologyOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT04123470 | A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma | completed | Phase 1 / Phase 2 | 24 | Lokon Pharma ABINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT04205227 | ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 137 | ENB Therapeutics, IncINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT05200143 | Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma | terminated | Phase 2 | 4 | Providence Health & ServicesOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02431676 | Survivorship Promotion In Reducing IGF-1 Trial(SPIRIT) | completed | Phase 2 | 121 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT04768881 | Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma | terminated | Phase 2 | 15 | Karyopharm Therapeutics IncINDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT06566391 | Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma | unknown | Phase 2 | 35 | European Institute of OncologyOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT05229614 | Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease(ICONIC) | unknown | Phase 2 | 27 | CNAO National Center of Oncological HadrontherapyOTHER | 2 | Aug 21, 2024 | clinicaltrials |
| NCT01256359 | Docetaxel With or Without AZD6244 in Melanoma(DOC-MEK) | completed | Phase 2 | 83 | University of OxfordOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT04951583 | Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma(FMT-LUMINATE) | unknown | Phase 2 | 45 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT03455764 | MCS110 With BRAF/MEK Inhibition in Patients With Melanoma | completed | Phase 1 / Phase 2 | 6 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT02535078 | Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Immunocore LtdINDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT05013099 | Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies(iPREDICT) | unknown | Phase 2 | 70 | ImaginAb, Inc.INDUSTRY | 6 | Jul 22, 2024 | clinicaltrials |
| NCT04198818 | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors | terminated | Phase 1 / Phase 2 | 37 | Haihe Biopharma Co., Ltd.INDUSTRY | 2 | Jul 19, 2024 | clinicaltrials |
| NCT03101254 | LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma | completed | Phase 1 / Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT01894672 | BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation | completed | Phase 2 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT04364230 | Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)(Mel66) | completed | Phase 1 / Phase 2 | 22 | Craig L Slingluff, JrOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06500091 | TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors | not yet recruiting | Phase 2 | 54 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 15, 2024 | clinicaltrials |
| NCT01585194 | Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma | completed | Phase 2 | 67 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT02981303 | Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer | completed | Phase 2 | 64 | HiberCell, Inc.INDUSTRY | 1 | Jul 9, 2024 | clinicaltrials |
| NCT04924413 | L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma | terminated | Phase 2 | 9 | Quanli GaoOTHER_GOV | 1 | Jul 3, 2024 | clinicaltrials |
| NCT02509598 | A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping | completed | Phase 2 | 24 | Cardinal Health 414, LLCINDUSTRY | 1 | Jun 28, 2024 | clinicaltrials |
| NCT02978404 | Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases | completed | Phase 2 | 26 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT05545969 | Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma(Neo PeLeMM) | withdrawn | Phase 2 | 0 | Melanoma Institute AustraliaOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03755739 | Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors | recruiting | Phase 2 / Phase 3 | 200 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06470880 | Circulating Tumour DNA Guided Adaptive BRAF and MEK Inhibitor Therapy(DyNAMIc) | not yet recruiting | Phase 2 | 40 | The Christie NHS Foundation TrustOTHER | 0 | Jun 24, 2024 | clinicaltrials |
| NCT05060432 | Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors(TIG-006) | unknown | Phase 1 / Phase 2 | 153 | iTeos Belgium SAINDUSTRY | 6 | Jun 21, 2024 | clinicaltrials |
| NCT03484923 | Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma(PLATforM) | completed | Phase 2 | 196 | Novartis PharmaceuticalsINDUSTRY | 10 | Jun 18, 2024 | clinicaltrials |
| NCT02631447 | Sequential Combo Immuno and Target Therapy (SECOMBIT) Study(SECOMBIT) | completed | Phase 2 | 251 | Fondazione Melanoma OnlusOTHER | 10 | Jun 7, 2024 | clinicaltrials |
| NCT01119508 | Ipilimumab + Temozolomide in Metastatic Melanoma | completed | Phase 2 | 64 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT04655157 | Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma(QUAD01) | terminated | Phase 1 / Phase 2 | 2 | Jason J. Luke, MDOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT02107755 | Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 8 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT05955105 | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 200 | Innolake BiopharmINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT01740297 | Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma | completed | Phase 1 / Phase 2 | 217 | AmgenINDUSTRY | 3 | May 14, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Nov 15, 2024source: clinicaltrials